1448038-91-2

Basic information

• Product Name: 5-bromo-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]
• Synonyms: 5-bromo-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]
• CAS NO: 1448038-91-2
• Molecular Weight: 482.438
• Mol File: 1448038-91-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-bromo-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran](CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran](1448038-91-2)
• EPA Substance Registry System: 5-bromo-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran](1448038-91-2)

Safety Data

• Hazardous Substances Data: 1448038-91-2(Hazardous Substances Data)

Upstream product

• 349-88-2 4-Fluorobenzenesulfonyl chloride 
• 1448038-85-4 5-bromo-2-cyclopropyl-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran] 
• 50675-19-9 4-thianylcarbaldehyde 
• 100277-27-8 (tetrahydro-2H-thiopyran-4-yl)methanol 
• 131992-30-8 4-(methoxymethylene)-3,4,5,6-tetrahydro-2H-thiopyran 

Downstream Products

• 1448039-59-5 (R)-N-(2-chlorobenzyl)-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxamide 
• 1448039-60-8 (S)-N-(2-chlorobenzyl)-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxamide 
• 1448041-28-8 N-(2-chlorobenzyl)-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxamide 1'-oxide 
• 1448039-62-0 rac-N-[(3-chloropyridin-2-yl)methyl]-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxamide 1',1'-dioxide 
• 1448040-74-1 2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-N-{[(5-trifluoromethyl)pyridin-2-yl]methyl}-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxamide 1',1'-dioxide 
• 1448041-24-4 N-{2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1',1'-dioxido-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-yl}cyclopropanecarboxamide 
• 1448039-18-6 methyl 2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxylate 1',1'-dioxide 
• 1448039-26-6 2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxylic acid 1',1'-dioxide 
• 1448039-38-0 2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran] 1',1'-dioxide 
• 1448039-39-1 2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-5-nitro-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran] 1',1'-dioxide 
• 1448039-40-4 2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-amine 1',1'-dioxide 
• 1448039-58-4 N-(2-chlorobenzyl)-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxamide 

Relevant articles and documents

Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women

The growth of uterine fibroids is sex hormone-dependent and commonly associated with highly incapacitating symptoms. Most treatment options consist of the control of these hormonal effects, ultimately blocking proliferative estrogen signaling (i.e., oral contraceptives/antagonization of human gonadotropin-releasing hormone receptor [hGnRH-R] activity). Full hGnRH-R blockade, however, results in menopausal symptoms and affects bone mineralization, thus limiting treatment duration or demanding estrogen add-back approaches. To overcome such issues, we aimed to identify novel, small-molecule hGnRH-R antagonists. This led to the discovery of compound BAY 1214784, an orally available, potent, and selective hGnRH-R antagonist. Altering the geminal dimethylindoline core of the initial hit compound to a spiroindoline system significantly improved GnRH-R antagonist potencies across several species, mandatory for a successful compound optimization in vivo. In a first-in-human study in postmenopausal women, once daily treatment with BAY 1214784 effectively lowered plasma luteinizing hormone levels by up to 49%, at the same time being associated with low pharmacokinetic variability and good tolerability.

SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS

Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selded from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reprodudive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.